The FDA's 2026 Peptide Vote: Its Scientists Said No, the Panel Said Yes. What Now?

Last checked: October 29, 2026. Educational content, not legal advice.

The 30-second answer

In July 2026, an FDA advisory panel voted to recommend six of seven peptides for pharmacy compounding. FDA's own scientists had said no to all seven. The vote was advice, not approval. On October 28, HHS opened a narrow, interim pharmacy pathway for those six. None is on the official list yet.

The surprise in the room

FDA's scientists reviewed seven peptides and recommended against every one. Then the outside experts voted, and six of the seven passed.

That split is why the headlines got loud. It's also why it pays to read what the vote did, and what it didn't.

In this article you'll learn:

• How each of the seven peptides fared, vote by vote
• Why FDA's own reviewers said no
• What the October 28 HHS policy changed, and what's still unchanged

What was the vote actually about?

The panel is FDA's Pharmacy Compounding Advisory Committee (PCAC), a group of outside experts. It met on July 23–24, 2026. ^[1]

The question: should seven peptides go on the 503A bulks list? That's FDA's list of raw ingredients state-licensed pharmacies can use to mix a drug for one patient. Think of it as an approved pantry. If an ingredient isn't on the shelf, pharmacies generally can't cook with it.

Advisory panels are like a movie test screening. The studio usually listens, but it still makes the final cut. FDA's meeting page puts it plainly. Committees "make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so."

Each peptide got two votes. One covered the free base (the peptide on its own). One covered the acetate (the peptide paired with acetate, a common salt form). ^[4]

How did each peptide do?

A note on sources: As of October 29, FDA's meeting page has the agenda, briefing papers, voting questions and official webcast links. It has no minutes or vote summary yet. The tallies above match two independent law-firm reports of the webcast, except where flagged. Published reports give one tally per peptide, covering both forms. ^[2]

Did you know? Emideltide, a sleep-related peptide, missed by a single vote: 6 yes, 7 no. It's the only one of the seven left out of the HHS policy.

What this means for you: Six peptides cleared an advisory hurdle. That puts them one step closer to a pharmacy list. It doesn't make any of them an approved drug.

Why did FDA's scientists say no?

FDA's briefing proposed that none of the seven be listed, in either form. ^[3]

FDA judges a bulk ingredient on four things, set in a 2019 rule. Is it well characterized chemically? Is it safe? Is there evidence it works? Has it been used in compounding before? FDA weighs them together.

For BPC-157, FDA flagged immunogenicity (the risk of an immune reaction to the peptide). It also flagged impurity and characterization problems. FDA wrote that it "lacks sufficient information to know whether the drug would cause harm when administered to humans." ^[11]

Did you know? For KPV, MOTS-c and the TB-500 fragment, FDA said it hadn't found any human exposure data at all. ^[11]

One more twist: every nomination had been withdrawn before the meeting. FDA "elect[ed] to proceed" anyway. ^[3]

What this means for you: The scientific record behind these peptides is thin. That's FDA's own reading, not ours.

Does a "yes" vote mean approval?

No. Here's the split.

A 503B outsourcing facility is a larger, FDA-registered compounder that works under factory-style quality rules. The HHS policy names only state-licensed pharmacies, federal facilities and licensed physicians.

What happened after the vote?

What does the October 28 policy require?

Enforcement discretion means an agency chooses not to enforce a rule under set conditions. It's like a city saying it won't ticket cars on one street while it rewrites the parking rules. The rule itself hasn't changed.

HHS says it won't act against a pharmacy or physician compounding one of the six peptides. But only when all of these hold: ^[8]

1. The peptide is on the policy's list and matches its named form and routes.
2. The raw powder comes from an FDA-registered maker that follows CGMP (FDA's manufacturing quality rules).
3. It has a full COA, a lab report card for that batch, graded "Intended for human drug compounding."
4. There's a patient-specific prescription, and the product has one active ingredient.
5. Serious side effects and quality problems go to MedWatch, FDA's safety reporting system, and to the states.
6. The label reads "This is a compounded drug product. Not for resale."
7. Oral forms come with proof of adequate absorption by mouth in humans.
8. The only device packed with it is an FDA 510(k)-cleared syringe.

HHS calls the policy interim. It says it can revisit it "if, among other things, a safety signal or product quality issue arises." The policy runs until a final rule settles each peptide, so rulemaking continues.

Myth vs. fact

What should researchers take from this?

Nothing in the vote or the policy changes what a research-grade peptide is. It's a lab reagent, sold without human-use claims.

What changed is the benchmark. HHS has now published, in detail, the COA it expects for compounding-grade material. You can use the same list to judge a supplier's paperwork:

• Identity confirmed two ways, for example HPLC plus mass spectrometry (a scale that weighs the molecule)
• HPLC purity with the trace attached. HPLC is a race where each molecule crosses the finish line at its own time.
• Endotoxin, bioburden, residual solvent and heavy-metal results. Endotoxin is the "smoke" dead bacteria leave behind.
• Lot number, test date and the testing lab's name

Read next:

• Is BPC-157 legal? 2026 status
• Are research peptides legal in the US?
• BPC-157 research overview
• TB-500 and thymosin beta-4 research
• Epithalon research and the 2026 PCAC vote
• Semax research and the 2026 PCAC vote

The evidence in detail

What FDA reviewed, peptide by peptide

Sources: "Use FDA reviewed" from the FDA meeting page and Federal Register notice 91 FR 20465 ^[5]. "FDA staff position" from the FDA briefing introduction, items 1–14. HHS forms and routes from the HHS policy, Appendix B.

Where the tallies come from

• Official record: FDA's July 23 and July 24 webcasts, linked from the meeting page. FDA had posted no minutes as of Oct 29, 2026.
• Reports of the webcast: McDermott Will & Schulte (Jul 27, 2026) gives epitalon 7–4–1 and semax 8–5–1. ArentFox Schiff (Jul 31, 2026) gives epitalon 7–5–1 and semax 8–5. Both agree on the other five tallies.
• Two votes per peptide: FDA's voting questions asked about free base and acetate separately. Published reports give one tally per peptide.

FDA's 2019 criteria

FDA evaluates a bulk substance on physical and chemical characterization, safety, evidence of effectiveness, and historical use in compounding. It weighs them together. ^[3]

---

Educational content, not legal advice. Laws and enforcement policies change; check the primary sources below and consult a qualified attorney for your situation.

For research use only. Not for human consumption. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

References

FDA and federal primary sources

1. FDA. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda, uses evaluated, event materials, official webcast links, docket FDA-2025-N-6895; page modified Aug 6, 2026). www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24…
2. FDA official webcasts, linked from ref 1: July 23, 2026 youtube.com/live/DhDC0DAYdBI ; July 24, 2026 youtube.com/live/xXM5ecHxlMU
3. FDA. PCAC Briefing Document Introduction (nominations withdrawn; FDA proposes none be listed). www.fda.gov/media/193342/download
4. FDA. PCAC Questions (two votes per substance: free base and acetate). www.fda.gov/media/193711/download
5. Federal Register. PCAC notice of meeting, 91 FR 20465 (Apr 16, 2026), docket FDA-2025-N-6895. www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compo…
6. Regulations.gov docket FDA-2025-N-6895 (2,643 comments per FederalRegister.gov, Oct 29, 2026). www.regulations.gov/docket/FDA-2025-N-6895
7. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Federal Register doc. 2026-22192 (public inspection Oct 28; publication Oct 30, 2026), docket HHS-OASH-2026-0496, RIN 0910-ZD94. public-inspection.federalregister.gov/2026-22192.pdf (permanent: www.federalregister.gov/d/2026-22192)
8. HHS. Policy text with Appendices A and B. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretio…
9. FDA. Bulk Drug Substances Used in Compounding Under Section 503A. www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-com…
10. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (categories list, updated May 14, 2026). www.fda.gov/media/94155/download
11. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-…
12. FDA. Compounding and the FDA: Questions and Answers. www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions…
13. WADA. The Prohibited List. www.wada-ama.org/en/prohibited-list

Secondary reports of the tallies (used to read the webcast record)

14. McDermott Will & Schulte. "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting." Jul 27, 2026. Epitalon 7–4–1, semax 8–5–1. www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-p…
15. ArentFox Schiff. "The (Pep)Tides Turn: FDA Panel Recommends Six of Seven for Compounding." Jul 31, 2026. Epitalon 7–5–1, semax 8–5. www.afslaw.com/perspectives/alerts/the-peptides-turn-fda-panel-recomme…
16. Reuters. "US Health Secretary Kennedy opens access to some unapproved peptides." Oct 28, 2026. www.reuters.com/legal/litigation/us-health-department-allow-temporary-…
17. Buchanan Ingersoll & Rooney. "FDA Submits Interim Peptide Compounding Policy for White House Review." Oct 16, 2026. www.bipc.com/fda-submits-interim-peptide-compounding-policy-for-white-…
18. Partnership for Safe Medicines. "PSM files Citizen Petition with FDA to stop unsafe compounding of untested peptides." Posted Oct 21, 2026; says the petition was filed Friday, Oct 16 and covers BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon. www.safemedicines.org/2026/10/psm-files-citizen-petitio.html (opened 2026-10-29; petition PDF itself not opened)